Literature DB >> 2549344

Role of pertussigen (pertussis toxin) on the mouse protective activity of vaccines made from Bordetella species.

J J Munoz1, M G Peacock.   

Abstract

Pertussigen [pertussis toxin (Ptx)] from Bordetella pertussis, when detoxified, induces protection in mice to intracerebral challenge (ic) with virulent B. pertussis. In its native form, minute nonprotective doses promote the development of immunity induced by other antigens of B. pertussis. As little as 4 ng of Ptx, given with a nonprotective dose of 8 X 10(7) killed cells of the phase III Sakairi strain, promoted detectable protection to ic challenge. Native Ptx in doses of 0.4 to 400 ng did not protect mice, and vaccines made from strains not producing Ptx induced only weak protection. The marked enhancing action of Ptx was also observed with 5 micrograms of purified filamentous hemagglutinin and with vaccines made from other species of the Bordetella genus, such as B. parapertussis and B. bronchiseptica, but it was not observed with B. pertussis endotoxin. In addition, Ptx was still effective when given as late as 7 days after the vaccine. Antibodies to surface antigens of the challenge strain were demonstrated in sera of mice immunized with vaccines prepared with the different Bordetella species tested, but antibodies to Ptx were detected only in the sera of mice immunized with the wild-type B. pertussis strains. Glutaraldehyde detoxified Ptx does not have this action. Pretreatment of normal mice with Ptx, also enhanced the protective action of a mouse antiserum to a wild-type strain of B. pertussis. These observations show that antigens other than Ptx are responsible for the protection, and that Ptx acts non-specifically to enhance the mouse protective action of those antigens.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2549344     DOI: 10.1111/j.1348-0421.1989.tb01982.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  8 in total

1.  Cellular pertussis vaccine containing a Bordetella pertussis strain that produces a nontoxic pertussis toxin molecule.

Authors:  I Marsili; M Pizza; F Giovannoni; G Volpini; M Bartalini; R Olivieri; R Rappuoli; L Nencioni
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

2.  Lymphocyte receptors for pertussis toxin.

Authors:  C G Clark; G D Armstrong
Journal:  Infect Immun       Date:  1990-12       Impact factor: 3.441

3.  Identification of linear B-cell determinants of pertussis toxin associated with the receptor recognition site of the S3 subunit.

Authors:  M A Schmidt; B Raupach; M Szulczynski; J Marzillier
Journal:  Infect Immun       Date:  1991-04       Impact factor: 3.441

4.  Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough.

Authors:  L Nencioni; M Pizza; M Bugnoli; T De Magistris; A Di Tommaso; F Giovannoni; R Manetti; I Marsili; G Matteucci; D Nucci
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

5.  Pertussis toxin analog with reduced enzymatic and biological activities is a protective immunogen.

Authors:  A Kimura; K T Mountzouros; P A Schad; W Cieplak; J L Cowell
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

6.  Pertussis toxin-induced alterations of murine hepatic drug metabolism following administration of diphtheria and tetanus toxoids and pertussis vaccine adsorbed.

Authors:  S Ansher; W Thompson; J Bridgewater; P Snoy
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

7.  Quantitative priming with inactivated pertussis toxoid vaccine in the aerosol challenge model.

Authors:  Jon B Bruss; George R Siber
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

8.  The 70-kilodalton pertussis toxin-binding protein in Jurkat cells.

Authors:  G D Armstrong; C G Clark; L D Heerze
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.